CompletedPhase 3NCT01111383

A Single Arm 48-Week Follow-on Safety Study to a Core Study Comparing the Efficacy and Tolerability of Tobrineb®/Actitob®/Bramitob® Versus TOBI®

Studying Digestive tract malformation

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Chiesi Farmaceutici S.p.A.
Principal Investigator
Henryk Mazurek, Doctor
Klinika Pneumonologii i Mukowiscydozy, Instytut Gruzlicy i Chorob Pluc w Rabce Zdroj
Intervention
tobramycin(drug)
Enrollment
209 target
Eligibility
6 years · All sexes
Timeline
20092011

Study locations (20)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01111383 on ClinicalTrials.gov

Other trials for Digestive tract malformation

Additional recruiting or active studies for the same condition.

See all trials for Digestive tract malformation

← Back to all trials